Moderna Inc
MRNA25.025USD
-0.855-3.30%
Horário de mercado （ET）Cotações atrasadas em 15 min
9.73BValor de mercado
PerdaP/L TTM
Mais detalhes de Moderna Inc Empresa
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Informações da empresa
Código da empresaMRNA
Nome da EmpresaModerna Inc
Data de listagemDec 07, 2018
CEOMr. Stephane Bancel
Número de funcionários5800
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 07
Endereço325 Binney Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Telefone16177146500
Sitehttps://www.modernatx.com/
Código da empresaMRNA
Data de listagemDec 07, 2018
CEOMr. Stephane Bancel
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
27.57K
+2.56%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
17.51K
+3.35%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
27.57K
+2.56%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
17.51K
+3.35%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
COVID
84.00M
97.67%
RSV
2.00M
2.33%
Por RegiãoUSD
Nome
Receita
Proporção
Rest of the World
55.00M
63.95%
United States
31.00M
36.05%
Europe
0.00
0.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
COVID
84.00M
97.67%
RSV
2.00M
2.33%
Distribuição de ações
Atualizado em: ter, 19 de ago
Atualizado em: ter, 19 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.70%
Baillie Gifford & Co.
5.68%
BlackRock Institutional Trust Company, N.A.
5.05%
Fidelity Management & Research Company LLC
5.00%
State Street Global Advisors (US)
4.44%
Outro
69.14%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.70%
Baillie Gifford & Co.
5.68%
BlackRock Institutional Trust Company, N.A.
5.05%
Fidelity Management & Research Company LLC
5.00%
State Street Global Advisors (US)
4.44%
Outro
69.14%
Tipos de investidores
Investidores
Proporção
Investment Advisor
40.02%
Investment Advisor/Hedge Fund
14.45%
Hedge Fund
10.65%
Research Firm
5.04%
Corporation
4.65%
Individual Investor
2.55%
Bank and Trust
1.50%
Venture Capital
1.19%
Pension Fund
1.17%
Outro
18.79%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
2015
310.55M
79.82%
-10.63M
2025Q1
2127
325.75M
84.24%
-21.87M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
2023Q2
2461
301.15M
78.90%
-7.01M
2023Q1
2466
303.08M
78.58%
-1.88M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
40.25M
10.41%
+71.93K
+0.18%
Mar 31, 2025
Baillie Gifford & Co.
24.95M
6.45%
-13.94M
-35.85%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
17.87M
4.62%
-166.51K
-0.92%
Mar 31, 2025
Fidelity Management & Research Company LLC
20.83M
5.39%
+2.44M
+13.30%
Mar 31, 2025
State Street Global Advisors (US)
17.78M
4.6%
+201.32K
+1.15%
Mar 31, 2025
Two Sigma Investments, LP
8.26M
2.14%
+7.49M
+976.22%
Mar 31, 2025
Boston Biotech Ventures, L.L.C.
9.21M
2.38%
+160.31K
+1.77%
Mar 05, 2025
Geode Capital Management, L.L.C.
7.46M
1.93%
+215.24K
+2.97%
Mar 31, 2025
Theleme Partners LLP
7.24M
1.87%
-64.47K
-0.88%
Mar 31, 2025
D. E. Shaw & Co., L.P.
5.64M
1.46%
+3.87M
+218.66%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Nome
Proporção
WisdomTree US Quality Growth Fund
0%
John Hancock Fundamental All Cap Core ETF
0%
iShares ESG Aware MSCI USA Growth ETF
0%
DoubleLine Fortune 500 Equal Weight ETF
0%
Calvert US Select Equity ETF
0%
Invesco QQQ Income Advantage ETF
0%
Innovator Hedged Nasdaq-100 ETF
0%
Pacer Metaurus Nasdaq 100 Div Multiplier 600 ETF
0%
iShares Nasdaq-100 ex Top 30 ETF
0%
YieldMax Ultra Option Income Strategy ETF
0%
Ver Mais
WisdomTree US Quality Growth Fund
Proporção0%
John Hancock Fundamental All Cap Core ETF
Proporção0%
iShares ESG Aware MSCI USA Growth ETF
Proporção0%
DoubleLine Fortune 500 Equal Weight ETF
Proporção0%
Calvert US Select Equity ETF
Proporção0%
Invesco QQQ Income Advantage ETF
Proporção0%
Innovator Hedged Nasdaq-100 ETF
Proporção0%
Pacer Metaurus Nasdaq 100 Div Multiplier 600 ETF
Proporção0%
iShares Nasdaq-100 ex Top 30 ETF
Proporção0%
YieldMax Ultra Option Income Strategy ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
